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CASE PRESENTATION
A 39 year old male chef with previous right aorto-renal
artery surgical reimplantation at age 8 for reported
congenital renal artery stenosis presented to an outside
hospital with gastroenteritis including symptoms of
abdominal pain, nausea, diarrhea and vomiting. Past
medical history apart from previous surgery for congenital
renal artery stenosis was unremarkable. He was an active
tobacco user of one pack per day for the previous
20 years. There was no family history of premature
coronary disease. Examination revealed a blood pressure
of 210/100 mmHg, heart rate of 88 beats per minute and
respiratory rate of 16 per minute. Blood pressure
recordings were equal in both upper limbs. The radial,
brachial, femoral and distal lower limb pulses were
symmetrical and of normal volume. No bruits were
audible over the carotid, subclavian or femoral arteries.
The remainders of the cardiac, respiratory and abdominal
examinations were unremarkable apart from a surgical
scar as a result of previous renal artery surgery.
Medications included nifedipine 90 mg and enalapril
20 mg had been started one month earlier for worsening
hypertension. Laboratory profile on admission is shown in
(Table 1).
His blood pressure was controlled on oral and intravenous
antihypertensive therapy and his serum creatinine decreased
to 1.4 mg/100 ml after discontinuation of the angiotensin-
converting enzyme inhibitor and i.v. fluid replacement for
dehydration. Evaluation of his renal arteries by magnetic
resonance angiography and duplex ultrasound revealed high-
grade stenosis in the right renal artery (RA) to a normal-sized
right kidney (13 cm) and a small patent left RA to an atrophic
left kidney (6.9 cm). A technetium renogram established that
the right kidney accounted for 85% of the total renal function
and the left kidney 15%.
The patient was subsequently referred to our institution
for RA angiography. He received intravenous pre-hydrated
and oral n-acetylcysteine pre-procedure for renal protection.
Creatinine pre-procedure was 1.2 mg/100 ml. Angiography
revealed a 70–80% tubular stenosis in the right RA to aortic
anastomosis (Figure 1). A small patent left RA to an atrophic
left kidney was also visualized. A baseline pressure gradient of
100 mm Hg across the right renal artery stenosis (RAS) was
obtained. The lesion was dilated with a 4.5 20 mm Ultrasoft
balloon (Boston Scientific, Natick, MA, USA). This resulted
in a 460% residual stenosis and therefore a 6.0 24 mm
Genesis balloon expandable stent (Cordis, J&J, Miami, FL,
USA) was implanted. The stent was post dilated with
sequential 5.0, 6.0, and 7.0 mm balloons with a residual
30% stenosis and a translesional gradient of 20 mm Hg
(Figure 2).
The patient did well for 5 months on nifedipine 120 mg qd
before he presented with recurrent uncontrolled hypertension
(systolic blood pressure 190 mm Hg). A duplex ultrasound of
the right RA revealed a peak systolic velocity of 429 cm/sec,
end diastolic velocity of 206 cm/sec, and a resistive index of
0.52. Repeat angiography was performed in view of poorly
controlled blood pressure and duplex ultrasound findings.
This revealed a right RA in-stent restenosis (ISR) of 50% with
a translesional gradient of 55 mm Hg. Percutaneous angio-
plasty with a 6.0 mm balloon was performed at high pressures
with 30% residual stenosis (Figure 3).
After 6 months, the patient’s systolic blood pressure
became uncontrollable once again despite Toprol XL 100 mg
qd and Norvasc 10 mg qd. Renal arterial duplex ultrasono-
graphy revealed a peak systolic velocity of 476 cm/sec in the
proximal stented segment of the right RA with a renal-to-
aortic ratio of 3.0, suggestive of significant recurrent
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restenosis. Subsequent right RA angiography revealed a 50%
long segment tubular ISR with a translesional gradient of
80 mm Hg (Figure 4).
A decision was made to seek a vascular surgical opinion at
this stage. The patient under went surgical bypass 2 months
later with a reverse saphenous graft from the aorta to the
right RA. He made an excellent postoperative recovery and
his blood pressure remains well controlled on Toprol XL
100 mg qd, Norvasc 10 mg qd, and Diovan 80 mg qd.
CLINICAL DIAGNOSIS
Recurrent RAS and resultant hypertension in a young male
patient with previous history of RA bypass to the same
kidney as a child.
Table 1 | Laboratory parameters of the index patient at the
time of admission
Investigation Result (reference range)
Serum chemistry
Sodium 133.0 mmol/l (136–142 per liter)
Potassium 3.9 mmol/l (3.5–5.0 mmol/l)
Calcium 8.3 mmol/l (8.8–10.5 mmol/l)
Creatinine 5.5 mg/100 ml (0.7–1.3 mg/100 ml)
Blood urea nitrogen 79.0 mg/100 ml (9–25 mg/100 ml)
Blood glucose 87.0 mg/100 ml (54–118 mg/100 ml)
HgbA1C 4.9% (4.2–5.8%)
Blood count
Hemoglobin 15.2 g/100 ml (13.5–18 g/100 ml)
WBC 8.27 k/ml (4–10 k/ml)
Platelets 235.0 k/ml (150–450 k/ml)
Hematocrit 43% (40–54%)
Lipid panel
Cholesterol 147 mg/100 ml (140–199 mg/100 ml)
Triglycerides 72 mg/100 ml (35–150 mg/100 ml)
LDL 97 mg/100 ml (50–129 mg/100 ml)
HDL 36 mg/100 ml (36–60 mg/100 ml)
HDL, high-density lipoprotein; HgbA1C, hemoglobin A1C; LDL, low-density
lipoprotein; WBC, white blood cell.
Figure 1 | Initial renal artery angiography showing severe
proximal right renal artery stenosis (arrow).
Figure 2 | Renal artery angiography showing residual 30%
renal artery stenosis (arrow) after balloon angioplasty
and stent implantation.
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Figure 3 | Duplex ultrasound findings of Doppler waveform
spectral broadening, high peak-systolic and end-diastolic
velocities suggestive of high-grade restenosis of the right
renal artery.
Figure 4 | Renal artery angiography showing recurrent right
renal artery in-stent restenosis (arrow).
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CLINICAL FOLLOW-UP
The patient is currently 1-year post-surgical revascularization of
his RA and his blood pressure is adequately controlled on
Toprol XL 100 mg qd, Norvasc 10 mg qd, and Diovan 80 mg qd.
DISCUSSION
Percutaneous transluminal angioplasty with stent implanta-
tion has been shown to be effective in the treatment of
atherosclerotic RA stenosis. Analogous to stenting in the
coronary artery, long-term efficacy of RA stenting is limited
by ISR in up to 20% of patients. We describe an interesting
case of recurrent RAS in a young man with surgical
revascularization of RAS as a child, which highlights the
potential limitations of percutaneous RA interventions.
Renal artery stenosis
The differential diagnosis of RAS in a young male patient
includes RA atherosclerosis, fibromuscular dysplasia, and
indeed possibly connective tissue disease such as Wegener’s
granulomatosis. RA atherosclerosis tends to occur in older
patients than the case presented and also associated with risk
factors, such as diabetes, smoking, hyperlipidemia, associated
coronary or peripheral vascular disease, and family history.
Fibromuscular dysplasia, formerly called fibromuscular
fibroplasia, is a group of nonatherosclerotic, noninflamma-
tory arterial diseases that can affect almost any artery, but
most commonly involves the renal arteries and usually occurs
in young female patients. Wegeners granulomatosis is an
inflammatory vasculitis of medium-to-large arterial vessels
that can also cause RAS.
RAS has become increasingly recognized as a contributing
factor to resistant hypertension, deterioration in renal
function, recurrent ‘flash pulmonary edema’, and long-term
ill effects of poorly controlled hypertension. RAS is prevalent
in patients with atherosclerotic vascular disease affecting
other vascular territories. In one series of 395 arteriograms
performed in patients with abdominal aortic aneurysms,
aortoiliac atherosclerosis, or infrainguinal atherosclerosis,
33–50% had an RAS of 450%.1 In a prospective study of
1302 patients undergoing coronary arteriography, concurrent
abdominal aortography demonstrated significant RAS in
15% of patients.2 More recent prospective data using duplex
ultrasonography to assess RA patency demonstrated that 48%
of renal arteries whose baseline stenosis was o60%
progressed to 460% stenosis after 36 months, compared
with only 8% in vessels with no stenosis at baseline.3
Older comparative trials have shown that stenting and
surgery are more effective than balloon angioplasty in
restoring RA patency, but neither resulted in better clinical
outcomes.4,5 A meta-analysis (Table 2) has demonstrated that
balloon angioplasty is more effective than antihypertensive
drug therapy in reducing blood pressure among hypertensive
patients with atherosclerotic RAS. The magnitude of the
difference, however, is modest, and it remains to be
determined whether this benefit will persist in the longer
term and improve clinical outcomes.6–8 In the pooled analysis
using the 12-month instead of the 3-month follow-up
data for the Dutch Renal Artery Stenosis Intervention
Cooperative trial, angioplasty was still favored, although the
difference for systolic blood pressure was no longer
statistically significant.
CORAL is an ongoing randomized clinical trial of patients
with RAS contrasting optimum medical therapy alone to
stenting with optimum medical therapy on a composite
cardiovascular and renal end point: cardiovascular or renal
death, myocardial infarction, hospitalization for congestive
heart failure, stroke, doubling of serum creatinine, and need
for renal replacement therapy. The secondary end points will
evaluate the effectiveness of revascularization in important
subgroups of patients and with respect to all-cause mortality,
kidney function, RA patency, microvascular renal function,
and blood pressure control.9 The results will provide a greater
understanding of RA revascularization versus medical
therapy.
RA stenting has emerged as the preferred endovascular
therapy for patients suffering from RAS. This procedure is
largely performed with very good technical results, good
anatomical results, and a low complication rate. By and large,
endovascular therapy has supplanted open RA reconstruction
in the United States10 secondary to the perceived lower
morbidity and mortality by referring physicians and patients.
The beneficial short- and long-term results of RA stent
placement have resulted in a rapid increase in stent use in the
treatment of RAS. Unfortunately, the long-term beneficial
effect of RA stent placement is limited by a restenosis rate of
between 9 and 25%.11,12 Recent data in relation to blood
pressure control concluded that patients with resistant or
difficult-to-control hypertension showed the greatest im-
provement in blood pressure control after RA stenting.13
However, results to date have been less favorable in terms of
improving associated renal insufficiency.14–18 This may be
secondary to procedure-related atheroembolization19,20 or
perhaps shortcomings in study design and power, inadequate
to demonstrate such a benefit.
Monitoring after RA intervention is extremely important
and probably best served by duplex ultrasound in terms of
cost effectiveness and lack of burden for the patient. Mahler
and colleagues have previously shown in a prospective
clinical study that 73% of renal arteries were patent 12
months after primary RA intervention.21 With consistent
Table 2 | Studies comparing the effects of medical therapy
with balloon angioplasty for the treatment of hypertension
with renal artery stenosis
No of patients
Study Angioplasty Medical therapy
DRASTIC6 56 30
EMMA7 23 26
SNRASCG8 25 30
DRASTIC, Dutch Renal Artery Stenosis Intervention Cooperative trial; EMMA, Essai
Multicentrique Medicaments vs Angioplastie trial; SNRASCG, Scottish and Newcastle
Renal Artery Stenosis Collaborative Group trial.
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duplex ultrasound follow-up and catheter reintervention in
cases of restenosis, the 12 month patency rate was increased
to 94% overall.
Renal artery in-stent restenosis
RA ISR, similar to coronary artery ISR, is due to neointimal
hyperplasia, a pathological process where stent placement
disrupts the intima of the artery and acts as a stimulus
for neointimal proliferation. Histologically, this process is
due to smooth muscle cell proliferation and migration
and abnormal endothelial remodeling. The optimal treat-
ment of RA ISR is not well established as there is currently a
paucity of data regarding which strategy is best. Treatments
for ISR of renal arteries include percutaneous transluminal
renal angioplasty (PTRA), repeat stent placement (bare metal
stents (BMSs), drug eluting stents (DESs), or covered stents),
brachytherapy, and cutting balloon angioplasty.
Drug eluting stents have significantly reduced the
incidence of ISR in coronary arteries. Recently, a nonrando-
mized prospective study evaluated the efficacy of sirolimus
DES compared to BMS in the treatment of atherosclerotic
RAS. This small study with 105 patients concluded that the
angiographic outcome at 6 months did not show a significant
difference between BMS and DES. However, RA stenting with
both types of stent was associated with significantly improved
blood pressure. Future studies with a larger patient popula-
tion and longer angiographic follow-up are warranted to
determine the efficacy of DES in the treatment of RAS.
Repeat RA stenting is thought preferably to PTRA alone
for RA ISR as the 6-month results of standalone PTRA for
RA ISR are disappointing with significant restenosis rates
between 36 and 67%. By comparison, DES was associated
with superior 6-month patency in a recent case report.22 A
recent prospective study concluded that balloon angioplasty
and the implantation of a BMS, a covered stent, or a
DES seemed to offer favorable long-term patency compared
to cutting balloon angioplasty in the treatment of
recurrent RA ISR.23 There are no large series of patients or
randomized trials using brachytherapy for ISR of renal
arteries although case reports have shown patency at 22
months and 4 years.24,25
Congenital renal artery stenosis
Severe arterial hypertension in neonates is often due to RAS.
Other causes include RA hypoplasia, abdominal aortic
atresia, co-arctation of the aorta, cystic kidney disease, and
reflux nephropathies.26 Fibromuscular dysplasia is the most
frequent cause of isolated RAS in this circumstance.27
Occasionally, accessory stenotic renal arteries exist. In
neonates, umbilical artery catheter placement is the most
frequent cause of RA thrombosis resulting in renovascular
hypertension.28 It must be stated that unilateral RAS in a
single functioning kidney in neonates or infants is potentially
a harmful condition associated with severe hypertension,
progressive renal failure, and a high risk of morbidity and
mortality.
To date, medical therapy remains the initial treatment
for neonatal hypertension with nephrectomy reserved in
cases of severe renal hypertension refractory to medical
therapy.29,30 Although blood pressure may be controlled in
such cases, follow-up imaging often shows severe atrophy of
the affected kidney.31 In infants with RAS, it was historically
thought necessary to manage the child medically until they
are older and open repair of the vascular abnormalities was
deemed feasible.32 Surgical reconstructive procedures include
surgical dilatation, RA resection and reanastomosis, and
autologous or synthetic bypass grafts, and autotransplanta-
tion have had good long-term results in many patients,
but may sometimes result in primary or secondary
nephrectomy.33,34
Medical therapy of hypertension in congenital RAS is
extremely important especially in patients with congenital
RAS in a solitary functioning kidney. In the latter type of
patients however, refractoriness to medical therapy is
common. Its pathogenesis can be explained by the model
of one-kidney, one-clip Goldblatt hypertension, in which
renal hypoperfusion leads to hyperactivation of the renin–
angiotensin–aldosterone system with a consequent circula-
tory volume expansion that cannot be modulated by pressure
natriuresis by means of the unaffected kidney. Pharmaco-
logical blockade of the renin–angiotensin–aldosterone system
may result in acute renal failure.35 Therefore, medical therapy
accompanied by little compensatory renin release and
minimal effect on glomerular filtration rate, such as labetalol
and a-adrenergic blocking agents, is preferred.
Currently, percutaneous transluminal angioplasty with or
without stent implantation is considered the first-line
treatment for RAS in adults and in adolescents. Overall,
good results from endovascular treatment appear to out-
weigh the risks of recurrent stenosis and rare but severe
complications such as RA dissection, rupture, or occlusion,
retroperitoneal bleeding or aneurysmal formation.36–38 In
infants, the utility of endovascular technique may be limited
due to small vessel size and the overall experience in small
children is limited.39,40
CONCLUSION
This difficult case highlights some important clinical issues
regarding RAS. Despite the lack of randomized data, there is
still nonetheless good evidence to suggest that RA stenting is
technically feasible and safe, improves renovascular hyperten-
sion, and to a lesser degree improves renal function. ISR
remains a significant limitation to endovascular techniques,
especially when PTRA and or stenting fail to achieve optimal
vessel dilatation, as in our case with previous RA bypass
surgery. Surgical treatment is still important in the manage-
ment of RAS, particularly in patients that have failed
percutaneous treatment.
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